zodasiran
Sponsor Arrowhead Pharmaceuticals, INC. · listed as ARWR
zodasiran is a drug asset sponsored by Arrowhead Pharmaceuticals, INC., listed as ARWR. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Aug 20, 2027 (day precision, medium confidence), tied to trial NCT07037771. That trial is in Phase 3 and currently active not recruiting, studying Homozygous Familial Hypercholesterolemia. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for zodasiran in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT07037771 catalyst | Phase 3 | Active, not recruiting | 2027-08-20 | Experimental | Arrowhead Pharmaceuticals | Homozygous Familial Hypercholesterolemia |
| NCT07473843 | Phase 3 | Not yet recruiting | 2028-07 | Experimental | Arrowhead Pharmaceuticals | Homozygous Familial Hypercholesterolemia |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More ARWR catalysts